Premium
ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma
Author(s) -
Onda Masanori,
Matsuda Satoru,
Higaki Shozo,
Iijima Takuo,
Fukushima Junichi,
Yokokura Akira,
Kojima Tatsuyoshi,
Horiuchi Hajime,
Kurokawa Takahide,
Yamamoto Tadashi
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960101)77:1<71::aid-cncr13>3.0.co;2-5
Subject(s) - osteosarcoma , erbb , medicine , immunohistochemistry , cancer research , concordance , exact test , pathology , cancer
BACKGROUND It has been reported that the c‐ erb B‐2 protooncogene is frequently amplified and overexpressed in many types of cancers, except sarcomas and hematological malignancies. METHODS Expression of ErbB‐2 in the tumors of 26 patients with conventional osteosarcoma was evaluated by immunoblotting. DNA from osteosarcoma tissues that expressed ErbB‐2 were analyzed by Southern blot hybridization to examine gross rearrangement of the gene. The DNA was also surveyed for the presence of genetic mutation in the transmembrane domain of ErbB‐2 by polymerase chain reaction–single‐stranded DNA conformation polymorphism analysis. In addition, possible correlation of ErbB‐2 expression with gender, age, histopathologic subtype, and response to chemotherapy was analyzed. Survival analysis was performed by the Kaplan‐Meier test using the approximate chi‐square statistic for the log‐rank test. RESULTS The ErbB‐2 protein was detected in 11 of 26 osteosarcoma tissues (42%) by immunoblot analysis. Expression of ErbB‐2 was confirmed by immunohistochemical studies using specific anti‐ErbB‐2 monoclonal antibody. However, neither amplification of the c‐ erb B‐2 gene nor evidence of significant genetic mutation was found in these osteosarcomas. Expression of ErbB‐2 examined by immunoblotting was most strongly correlated with early pulmonary metastases ( P < 0.05). Among the entire group of 26 patients in this study, Kaplan‐Meier life table survival of the patients with apparent ErbB‐2 expression was significantly worse than that of the patients with little ErbB‐2 expression ( P < 0.01). CONCLUSIONS In 42% of the osteosarcomas, the tumor cells expressed ErbB‐2. Expression of ErbB‐2 was strongly correlated with early pulmonary metastasis and poor survival rate for the patient. These data suggest that ErbB‐2 plays a significant role in aggressive tumor growth and in the promotion of metastatic potential in osteosarcomas. ErbB‐2 in the osteosarcoma tissues would be a useful prognostic marker for patients. Cancer 1996;77:71‐8.